

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date  
2 June 2005 (02.06.2005)

PCT

(10) International Publication Number  
**WO 2005/049576 A1**

(51) International Patent Classification<sup>7</sup>: C07D 217/14,  
217/22, A61K 31/472, A61P 35/00

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number:  
PCT/EP2004/013075

(22) International Filing Date:  
17 November 2004 (17.11.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0326964.4 19 November 2003 (19.11.2003) GB

(71) Applicant (for all designated States except US): **GLAXO GROUP LIMITED [GB/GB]**; Glaxo Wellcome House, Berkeley Avenue, Greenford Middlesex UB6 0NN (GB).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **WASHIO, Yoshiaki** [JP/JP]; Tsukuba Research Labs, 43 Wadai, Tsukuba-shi, Ibaraki 300-4247 (JP).

(74) Agent: **LEAROYD, Stephanie, Anne**; GlaxoSmithKline, Corporate Intellectual Property (CN925.1), 980 Great West Road, Brentford Middlesex TW8 9GS (GB).

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

---

(54) Title: SUBSTITUTE ISOQUINOLINES USEFUL IN THE TREATMENT OF DISEASES SUCH AS CANCER AND ATHEROSCLEROSIS



(57) Abstract: A compound of Formula (I) wherein: One of R<sup>1</sup> and R<sup>2</sup> is H and the other represents -NHCONHR<sup>4</sup> wherein R<sup>4</sup> represents a phenyl or naphthyl group (which may be optionally substituted by one or more substituents independently selected from -C<sub>1-6</sub> alkyl, -C<sub>1-6</sub> haloalkyl, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-, halogen, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> haloalkoxy, OH, NO<sub>2</sub>), C<sub>3-7</sub> cycloalkyl or R<sup>4</sup> together with the NH to which it is bonded forms a morpholino group and R<sup>3</sup> is H or NHR<sup>5</sup> wherein R<sup>5</sup> is H, -quinolinyl or -isoquinolinyl, -(CONH)<sub>p</sub> phenyl (wherein p is 0 or 1 and the phenyl is optionally substituted by one or more substituents independently selected from halogen, -C<sub>1-6</sub> alkyl, -C<sub>1-6</sub> haloalkyl, -morpholino, -SO<sub>2</sub>NH<sub>2</sub>, benzothiazole (substituted by methyl) or a salt, solvate, or physiologically functional derivative thereof.